Use of the Unapproved 'Wolverine' Peptide BPC-157 Is Rising Sharply, a New Medical-Records Analysis Reports

A peptide that most physicians have never prescribed is quietly showing up in more and more patient charts. A preliminary analysis of more than 15 million U.S. medical records, reported by Reuters on September 16, 2026, found that documented use of BPC-157, an unapproved peptide popular in fitness and longevity circles, has climbed sharply since 2020.

The analysis, from the data-analytics firm nference, was released ahead of peer review, so its findings are preliminary and not yet independently vetted. Even so, it is one of the first attempts to measure real-world use of a substance that is sold largely through a gray market and that the FDA has not approved for any use. Here is what the analysis reported, the safety signals that accompany it, and how it connects to a July 2026 FDA advisory vote on peptide compounding.

What the analysis reported

According to Reuters, nference reviewed more than 15 million medical records and identified 1,039 patients whose doctors had manually noted BPC-157 use in written clinical notes. The number of new confirmed users increased roughly 33-fold between 2020 and 2026. Because the count depends on clinicians happening to record the drug in free-text notes, the true number of users is almost certainly higher. The firm's lead scientist, Venky Soundararajan, was quoted saying that very few doctors are even asking their patients whether they are taking BPC-157, which suggests the documented cases are a fraction of actual use.

The analysis was posted ahead of peer review. That means the numbers have not yet been independently checked by other researchers, and they should be read as an early estimate rather than a settled finding.

Who is using it, and why

The reporting describes a user base that shifted over the study window. The share of new users who were male rose from about 57 percent in 2020 to about 70 percent in 2026, and the average age fell from about 55 to 49. Reasons for use were documented for 644 of the patients and spanned sports injuries, chronic pain, and gastrointestinal disorders, uses that track the healing and recovery claims promoted for the peptide online. The analysis reportedly recorded a response to treatment for only about a third of patients, and outside experts stressed that observational chart data cannot establish whether the peptide actually works.

What the 'Wolverine stack' is

BPC-157 is a synthetic peptide often combined with TB-500 in a regimen that users nickname the 'Wolverine stack,' a reference to the comic-book character's rapid healing. It is marketed online for injury recovery, pain, and performance, claims that are not supported by large human trials. U.S. Health Secretary Robert F. Kennedy Jr. has publicly backed broader access to the peptide, which has helped raise its profile.

BPC-157 is not an FDA-approved drug. Products sold as research chemicals, often labeled not for human use, are not made to pharmaceutical quality standards, and their contents and purity are not verified by the FDA.

The safety signal

The rising use comes with a safety signal that regulators have started to log. Reuters reported that the FDA Adverse Event Reporting System has recorded 10 reports of people experiencing adverse events while using BPC-157 since 2021, and that all 10 were classified as serious. Eight of the 10 reports were filed in 2026, the same period in which the analysis found use accelerating. Adverse-event reports do not by themselves prove that a product caused harm, but a cluster of serious reports is the kind of pattern that safety monitors watch.

How this connects to the FDA compounding vote

The analysis lands months after a closely watched regulatory step. On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee voted to recommend BPC-157 and five other peptides for the Section 503A bulks list, the roster of substances that state-licensed pharmacies may compound. FDA career scientists had urged the panel to reject all seven peptides under review, citing thin human evidence, so the committee's recommendation broke with the agency's own reviewers.

That recommendation is advisory and non-binding. As the FDA's meeting page notes, advisory committees make recommendations that the agency generally considers but is not required to follow, and any addition to the compounding list would still have to go through a formal rulemaking process. In other words, the July vote signaled a possible future pathway for compounded BPC-157; it did not, by itself, approve the peptide or change what is legal to compound today.

What this means for telehealth patients

For readers who encounter BPC-157 through a telehealth clinic, a wellness provider, or a social-media seller, the practical takeaway is that demand is rising faster than the evidence. An unapproved peptide with a growing count of serious adverse-event reports, sold largely outside the regulated supply chain, carries quality and safety uncertainties that a marketing page will not disclose. This is general information for a telehealth audience, not medical advice. Anyone considering or already using a peptide should tell their own licensed clinician, who can weigh individual risks, and should rely on primary FDA documents rather than seller claims.

Limits and what is not settled

Several caveats apply. The analysis is preliminary and has not been peer reviewed, its counts rest on clinicians recording the drug in free-text notes and so undercount true use, and observational data cannot show whether BPC-157 is safe or effective. The adverse-event totals come from a passive reporting system that does not establish causation. The July FDA advisory vote remains a recommendation, not a rule, and no final rule adding BPC-157 to the compounding list exists as of publication. None of the figures here should be read as an endorsement of the peptide.